PEGylated IL-10 for Solid Tumor Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for various diseases and disorders associated with IL-10, such as inflammatory conditions, immune-related disorders, and cancer, face challenges in optimizing efficacy while minimizing adverse effects, particularly due to the short serum half-life of IL-10 and variability in pharmacokinetic and pharmacodynamic parameters.
Innovation Solution
The use of modified IL-10 agents, including pegylated IL-10, glycosylated IL-10, and albumin conjugates, which maintain a stable serum trough concentration for extended periods, optimizing dosing regimens to achieve and maintain therapeutic levels, and the administration of these agents via parenteral routes to enhance therapeutic efficacy and reduce immunogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If IL-10 is administered to treat solid tumors, then therapeutic efficacy is improved, but serum half-life is short leading to frequent dosing requirements
Solution Approach 1:
The patent uses polyethylene glycol (PEG) as an intermediary molecule to modify IL-10, creating PEG-IL-10 conjugates. The PEG moiety acts as a mediator that extends the circulation half-life of IL-10 without compromising its biological activity, thereby reducing dosing frequency while maintaining therapeutic efficacy in solid tumors
Solution Approach 2:
The patent modifies the physical-chemical parameters of IL-10 by conjugating it with PEG chains of varying molecular weights. This parameter change (increasing molecular size through PEGylation) alters the pharmacokinetic properties, specifically extending serum half-life and improving the duration of action while preserving immunosuppressive activity in the tumor microenvironment
2Reliability
If IL-10 dosing is optimized to maintain therapeutic levels, then treatment efficacy is improved, but adverse effects increase due to pleiotropic activity
Solution Approach 1:
The patent exploits the local quality difference between tumor and normal tissues by administering IL-10 at doses that achieve therapeutic levels specifically in the tumor microenvironment. The modified IL-10 agents accumulate preferentially in tumors, providing local immunosuppression where needed while minimizing systemic exposure and associated adverse effects
Solution Approach 2:
The patent employs partial action by using lower doses of modified IL-10 that are sufficient to achieve the desired immunosuppressive effect in tumors without reaching thresholds that would trigger systemic adverse effects. This partial dosing strategy maintains efficacy while reducing harm
3Ease of operation
If conventional IL-10 is used for treatment, then simplicity of administration is maintained, but pharmacokinetic variability reduces treatment consistency
Solution Approach 1:
The patent introduces PEGylation as a standardized intermediary modification that reduces pharmacokinetic variability. The PEG moiety provides consistent steric protection and extends half-life in a predictable manner, leading to more reliable and reproducible treatment outcomes while maintaining the simplicity of parenteral administration
Data Source
AI summary
Methods of treating subjects having a disease or disorder responsive to IL-10, including methods of administration and dosing regimens associated therewith, are provided.